Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
F14
- Development stage
- Phase 3
- Lead developer
- Arthritis Innovation
- Modality
- Implantable Hydrogels → Hydrogel Systems → Drug Delivery Systems, Small Molecules, Implantable Devices → Device-based Delivery → Drug Delivery Systems, Transdermal Patches → Device-based Delivery → Drug Delivery Systems, Injectable Hydrogels → Hydrogel Systems → Drug Delivery Systems
- Administration
- Intraarticular
01
Overview
F14 (also known as mdc-CWM) is a sustained-release formulation of the non-steroidal anti-inflammatory drug (NSAID) celecoxib. It is designed for intra-articular administration, meaning it is injected directly into the joint space. The formulation uses MedinCell's proprietary BEPO technology to provide controlled and extended release of celecoxib at therapeutic levels over several days, weeks, or months from a single injection. This approach aims to improve patient compliance and therapeutic outcomes by reducing dosing frequency and maintaining consistent drug levels[2].
- Other names
- sustained-release celecoxibintra-articular celecoxib
02
Targets
PTGS2 (Prostaglandin-Endoperoxide Synthase 2)PGHS-1 (Prostaglandin G/H Synthase 1)
Beyond the preview
Go deeper on F14.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on F14.